GlassScriptPhysician profile
Robert Petrossian
NPI 1942664370
$7,140.51
in general payments reported to CMS, 2019-2025
29 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $58.46 · 2021: $453 · 2022: $824 · 2023: $1,488 · 2024: $3,827 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,784 · Food and Beverage: $1,826 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,784.19 |
| Food and Beverage | $1,826.33 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $2,544.38 | 2024 | Monarch |
| Intuitive Surgical, INC. | $2,419.27 | 2022-2024 | Da Vinci Surgical System |
| Pulmonx Corporation | $386.96 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| United Therapeutics Corporation | $274.67 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Steris Corporation | $246.70 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $246.23 | 2021-2022 | |
| Ethicon INC. | $195.40 | 2024 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.21 | 2022-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $70.32 | 2022-2024 | Andexxa, Tezspire, Fasenra |
| Astellas Pharma US INC | $55.89 | 2021-2022 | |
| Genzyme Corporation | $51.27 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.04 | 2021 | |
| Procept Biorobotics Corporation | $38.09 | 2024 | Aquabeam System |
| Alexion Pharmaceuticals, INC. | $37.89 | 2021-2022 | |
| Edwards Lifesciences Corporation | $33.41 | 2024 | Hemosphere |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $30.68 | 2024-2025 | Gemtesa |
| Olympus America INC. | $28.14 | 2025 | Spiration Valve System |
| Mallinckrodt Hospital Products INC. | $22.89 | 2022 | |
| Erbe USA INC | $20.00 | 2024 | Vio3 Apc3 Cryo2 |
| Merck Sharp & Dohme LLC | $18.56 | 2024 | Winrevair |
| Glaxosmithkline, LLC. | $17.10 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $16.91 | 2021 | |
| Advanced Respiratory, INC | $15.47 | 2020 | |
| Mylan Specialty L.P. | $14.75 | 2019 | |
| Corcept Therapeutics | $14.53 | 2021 | |
| Philips North America LLC | $13.94 | 2025 | Vest Therapy Und |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2021 | |
| Sandoz INC. | $12.39 | 2021 | |
| Covidien LP | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Petrossian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.